Document:

<PAGE>
                                  EXHIBIT 10.1

                         ALPHARMA INC. AND SUBSIDIARIES
                 CONSOLIDATED CONDENSED PROFORMA BALANCE SHEET
                             AT SEPTEMBER 30, 2005
                      (in thousands, except share amounts)
                                  (Unaudited)

<TABLE>
<CAPTION>

                                                                                  Adjustment
                                                      Alpharma Inc.     Less        For Net
                                                            As        Generics       Sale        Alpharma Inc.
                                                         Reported     Business     Proceeds       Pro Forma
                                                      -------------   --------    ----------    -------------
<S>                                                   <C>             <C>         <C>           <C>
ASSETS
Current assets:
   Cash and cash equivalents                           $   59,028     $     --    $  221,723    $  280,751
   Accounts receivable                                    217,188      125,826                      91,362
   Inventories                                            240,060      148,761                      91,299
   Prepaid expenses and other current assets               16,784        2,223                      14,561
                                                       ----------     --------    ----------    ----------
      Total current assets                                533,060      276,810       221,723       477,973

Property, plant and equipment, net                        422,043      199,730                     222,313
Goodwill                                                  443,648      323,506                     120,142
Intangible assets, net                                    282,304      100,918                     181,386
Other assets and deferred charges                          68,671       20,574                      48,097
                                                       ----------     --------    ----------    ----------
      Total assets                                     $1,749,726     $921,538    $  221,723    $1,049,911
                                                       ==========     ========    ----------    ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Current portion of long-term debt                   $  167,571     $     --      (167,571)   $       --
   Short-term debt                                              4           --            (4)           --
   Accounts payable                                        97,353       67,251                      30,102
   Accrued expenses                                       185,826       91,126        19,000       113,700
   Accrued and deferred income taxes                       53,894       22,383                      31,511
                                                       ----------     --------    ----------    ----------
      Total current liabilities                           504,648      180,760      (148,575)      175,313

Long-term debt                                            330,702           --      (330,702)           --
Deferred income taxes                                      33,079       22,160                      10,919
Other non-current liabilities                              32,857       11,508                      21,349

Stockholders' equity:
   Common Stock                                            10,784           --                      10,784
   Additional paid-in capital                           1,084,689           --                   1,084,689
   Unearned compensation                                   (9,174)         (11)                     (9,163)
   Accumulated deficit                                   (307,811)     659,226    $  701,000      (266,037)
   Accumulated other comprehensive income                  77,596       47,895                      29,701
   Treasury stock, at cost                                 (7,644)          --                      (7,644)
                                                       ----------     --------    ----------    ----------
      Total stockholders' equity                          848,440      707,110       701,000       842,330
                                                       ----------     --------    ----------    ----------
         Total liabilities and stockholders' equity    $1,749,726     $921,538    $  221,723    $1,049,911
                                                       ==========     ========    ==========    ==========
</TABLE>

The Pro Forma Balance Sheet has been adjusted to include the estimated net
proceeds of approximately $720 million from the sale of the Generics business to
Actavis for $810 million. The adjustments include the repayment of all
outstanding debt with the net sale proceeds.

                                        1

<PAGE>

                         ALPHARMA INC. AND SUBSIDIARIES
                  CONSOLIDATED PROFORMA STATEMENT OF OPERATIONS
                    FOR NINE MONTHS ENDED SEPTEMBER 30, 2005
                (In thousands of dollars, except per share data)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                             Adjustment
                                                  Alpharma Inc.     Less      For Net
                                                        As        Generics     Sale         Alpharma Inc.
                                                     Reported     Business    Proceeds       Pro forma
                                                  -------------   --------   -----------   -------------
<S>                                               <C>             <C>        <C>           <C>
Total revenue                                      $1,095,155     $645,177                    $449,978
   Cost of sales                                      614,252      419,387                     194,865
                                                   ----------     --------                    --------
Gross profit                                          480,903      225,790                     255,113
   Selling, general and administrative expenses       303,581      136,858                     166,723
   Research and development                            58,862       39,315                      19,547
   Goodwill impairment                                    815          815                          --
                                                   ----------     --------                    --------
Operating income                                      117,645       48,802                      68,843
   Interest expense and amortization of
      debt issuance costs                             (37,467)        (328)     $37,139             --
   Loss on extinguishment of debt                      (2,373)          --                      (2,373)
   Other income, net                                    2,711        1,686                       1,025
                                                   ----------     --------     --------       --------
Income before income taxes                             80,516       50,160       37,137         67,495
   Provision for income taxes                          33,827       12,942                      20,885
                                                   ----------     --------     --------       --------
Net income                                         $   46,689     $ 37,218      $37,139       $ 46,610
                                                   ==========     ========     ========       ========
Earnings per common share:
   Basic                                           $     0.89     $   0.71     $   0.71       $   0.89
                                                   ==========     ========     ========       ========
   Diluted                                         $     0.88     $   0.70     $   0.70       $   0.88
                                                   ==========     ========     ========       ========
Weighted average shares:
   Basic                                               52,421       52,421       52,421         52,421
                                                   ==========     ========     ========       ========
   Diluted                                             52,800       52,800       52,800         52,800
                                                   ==========     ========     ========       ========
</TABLE>

The above Pro Forma Statement of Operations has been adjusted to reflect the
impact on results of operations that would result from the use of the estimated
net sale proceeds of approximately $720 million to repay all outstanding debt.
The use of proceeds to repay all debt would serve to eliminate the associated
interest expenses, the estimated effect of which is reflected in the Pro Forma
Statement of Operations.

The provision for Generic income taxes represents estimated income taxes for the
associated foreign entities, plus estimated U.S. state tax provisions. As part
of the American Jobs Creation Act of 2004, the Company has provided for federal
income taxes of approximately $9.4 million on the repatriation of accumulated
income earned outside the U.S. This amount is included in the provision for
income taxes within the "Pro Forma" column above.

                                        2

<PAGE>

                         ALPHARMA INC. AND SUBSIDIARIES
                  CONSOLIDATED PROFORMA STATEMENT OF OPERATIONS
                        FOR YEAR ENDED DECEMBER 31, 2004
                (In thousands of dollars, except per share data)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                              Adjustment
                                                  Alpharma Inc.      Less      For Net
                                                        As         Generics      Sale         Alpharma Inc.
                                                     Reported      Business    Proceeds          Proforma
                                                  -------------   ---------   ----------      -------------
<S>                                               <C>             <C>         <C>             <C>
Total revenue                                      $1,339,480     $ 749,221                     $ 590,259
   Cost of sales                                      806,442       529,452                       276,990
                                                   ----------     ---------                     ---------
Gross profit                                          533,038       219,769                       313,269
   Selling, general and administrative                384,959       179,863                       205,096
   Research and development                            81,466        56,035                        25,431
   Asset impairments and other                         29,742        18,632                        11,110
   Goodwill impairment                                260,000       260,000                            --
                                                   ----------     ---------                     ---------
Operating income                                     (223,129)     (294,761)                       71,632
   Interest expense and amortization of
      debt issuance costs                             (59,061)         (299)  $53,895              (4,867)
   Loss on extinguishment of debt                      (2,795)           --                        (2,795)
   Other income, net                                   31,387        30,149                         1,238
                                                   ----------     ---------                     ---------
Income (loss) before income taxes                    (253,598)     (264,911)   53,895              65,208
   Provision (benefit) for income taxes                61,139         2,325                        58,814
                                                   ----------     ---------   -------           ---------
Net income (loss)                                  $ (314,737)    $(267,236)  $53,895           $   6,394
                                                   ==========     =========   =======           =========

Earnings (loss) per common share:
   Basic                                           $    (6.05)    $   (5.13)  $  1.04           $    0.12
                                                   ==========     =========   =======           =========
   Diluted                                         $    (6.05)    $   (5.13)  $  1.04           $    0.12
                                                   ==========     =========   =======           =========

Weighted average shares:
   Basic                                               52,060        52,060    52,060              52,060
   Diluted                                             52,060        52,060    52,060              52,060
</TABLE>

The above Pro Forma Statement of Operations has been adjusted to reflect the
impact on results of operations that would result from the use of the estimated
net sale proceeds of approximately $720 million to repay outstanding debt. The
use of proceeds to repay debt would serve to reduce the associated interest
expense, the estimated effect of which is reflected in the Pro Forma Statement
of Operations.

The provision for Generic income taxes represents estimated income taxes for the
associated foreign entities, plus estimated U.S. state tax provisions. The
Company recorded an allowance related to deferred tax assets for its U.S.
operations in the fourth quarter of 2004 and has included this amount in the
provision for income taxes within the "Proforma" column above.

                                        3<PAGE>

                                  EXHIBIT 10.2

              AMENDMENT NO. 3 TO STOCK AND ASSET PURCHASE AGREEMENT

     This Amendment No. 3 (this "Amendment") to the Stock and Asset Purchase
Agreement, dated as of October 17, 2005 (the "Agreement"), by and among Actavis
Group hf., a corporation organized under the laws of Iceland ("Buyer"), Alpharma
Inc., a Delaware corporation ("Seller"), Alpharma Bermuda G.P., a Bermuda
general partnership ("Alpharma Bermuda"), Alpharma (Luxembourg) S.a.r.l., a
company organized under the laws of Luxembourg ("Alpharma S.a.r.l."), Cox
Investments Limited, a company organized under the laws of the United Kingdom
("Cox Investments"), Barre Parent Corporation, a Delaware corporation ("Barre"),
Purepac Pharmaceutical Holdings, Inc., a Delaware corporation ("Purepac
Holdings"), Alpharma U.S. Inc., a Delaware corporation ("Alpharma U.S."),
Alpharma (U.K.) Limited, a company organized under the laws of the United
Kingdom ("Alpharma U.K."), Alpha-Lux Investments S.a.r.l., a company organized
under the laws of Luxembourg ("Alpharma Luxembourg"), Alpharma ApS, a company
organized under the laws of Denmark ("Alpharma Denmark"), Alpharma Holding,
Inc., a Delaware corporation ("Alpharma Holding" and, collectively with Seller,
Barre, Purepac Holdings, Alpharma U.S., Alpharma Luxembourg and Alpharma
Denmark, the "Share Sellers"), and Alpharma AS, a company organized under the
laws of Norway ("Alpharma Norway" and, collectively with Alpharma Denmark and
Alpharma Luxembourg, the "Asset Sellers" and, collectively, with Buyer, Seller
and the Share Sellers, the "Parties"), as amended by the letter agreements
between Buyer and Seller dated as of October 17, 2005 ("Amendment No. 1") and
November 23, 2005 ("Amendment No. 2"), is entered into as of December __, 2005
by and among the Parties.

     The Parties desire to amend the Agreement as provided herein.

     Now, therefore, in consideration of the premises and the mutual promises
herein made, and in consideration of the representations, warranties, and
covenants herein contained, the Parties agree as follows.

     Amendments to the Agreement

     Amendments to Section 1 of the Agreement

          The following definitions are hereby added to Section 1 of the
Agreement:

     "Alpharma-Isis" means Alpharma-Isis GmbH & Co. KG, a partnership organized
under the laws of Germany.

                                        4

<PAGE>

     "Bermuda Note" means that certain promissory note dated as of December 19,
2003 issued by Alpharma Bermuda, as borrower, to Alpharma-Isis, as lender, for a
principal outstanding amount of E25,000,000, plus accrued interest, as
amended, supplemented or modified and as in effect as of the date of this
Agreement.

     "Initial German Loan" means the loan provided by Alpharma Bermuda to
Alpharma-Isis pursuant to the Loan Agreement dated 30 June 2000, as amended on 1
June 2003, with a principal amount of E134,697,967.17 and accrued but
unpaid interest of E14,390,753.72.

     "Retained German Loan" means that portion (with a principal amount of
E27,136,569.86 and accrued but unpaid interest of E2,899,195.01) of
the Initial German Loan to be held by Alpharma Bermuda following Closing, which
portion shall no longer bear interest.

          The following definitions set forth in Section 1 of the Agreement are
     hereby amended in their entirety to read as follows:

     "Assumed Liabilities" means (a) all liabilities and obligations of Seller
with respect to guarantees by Seller of any letters of credit and acceptances
(or instruments serving a similar function) issued or created for the account of
the Business, (b) all liabilities and obligations of Alpharma Bermuda under the
Bermuda Note and (c) all of the liabilities and obligations of the Asset Sellers
related to the Business (whether known or unknown, whether asserted or
unasserted, whether absolute or contingent, whether accrued or unaccrued,
whether liquidated or unliquidated, and whether due or to become due), as
described in Annex III attached hereto or as reflected on the Closing Date Pro
Forma Balance Sheet, including (i) all liabilities of the Asset Sellers for
unpaid Non-Income Taxes of the Asset Sellers relating to the Business for any
Pre-Closing Period, but only to the extent such Tax liabilities do not exceed
the reserve for Non-Income Tax liabilities included in the Closing Date Pro
Forma Balance Sheet, (ii) all liabilities and obligations of the Asset Sellers
under the agreements, contracts, leases, licenses, and other arrangements
related to the Business and assigned to Buyer in accordance with the terms of
this Agreement, (iii) all liabilities and obligations of the Asset Sellers
related to the Employees of the Business and former employees of the Business
employed by or formerly employed by the Asset Sellers to the extent expressly
assumed under Section 6(f) below, (iv) all liabilities arising out of any
personal injury and/or death or damage to property relating to or arising in
connection with the Products marketed, distributed, sold or otherwise provided
by, or on behalf of, any of the Asset Sellers, except to the extent Insurance
responds to any claims with respect to such liabilities that arise prior to the
Closing, (v) all liabilities and obligations of the Asset Sellers with respect
to any letters of credit and acceptances (or instruments serving a similar
function) issued or created for the account of the Business, and (vi) all
liabilities relating to the Pfizer Litigation; provided, however, that the
Assumed Liabilities shall not include (x) any Excluded Liabilities,

                                        5

<PAGE>

(y) any Retained Liabilities or (z) any liability or obligation of any of the
Sellers under this Agreement (or under any side agreement between any of the
Sellers on the one hand and Buyer on the other hand entered into on or after the
date of this Agreement).

     "Current Liabilities" means the sum of the dollar amounts reflected on the
Target Pro Forma Balance Sheet and the Closing Date Pro Forma Balance Sheet,
respectively, for accounts payable and accrued expenses and other items that
would be classified as "current liabilities" in accordance with GAAP; provided,
however, that accruals with respect to Income Taxes for any Pre-Closing Period,
Intercompany Payables, the Bermuda Note, Bonus Obligations, and any Retention
Arrangements shall be excluded from such sum.

     "German Loan" means a portion (with a principal amount of
E107,561,397.31 and accrued but unpaid interest of E11,491,558.71) of
the Initial German Loan to be held assigned to Buyer at Closing

     "Intercompany Payables" means obligations owed by an Asset Seller or a
Target Company or any Target Subsidiary to Seller or any of its Affiliates,
other than the German Loan, the Retained German Loan and the U.K. Note.

     "U.K. Note" means that certain promissory note, dated as of January 1,
2004, issued by Alpharma Holdings Limited, as borrower, to Alpharma S.a.r.l., as
lender, for a principal outstanding amount of L 48,196,732.00, and any
promissory notes or loans issued in respect of interest accrued thereon, as
amended, supplemented or modified and as in effect as of the date of this
Agreement.

          Subclause (h) of the definition of "Retained Liabilities" set forth in
     Section 1 of the Agreement is hereby amended in its entirety to read as
     follows: "(h) any Indebtedness of any of the Target Companies or their
     Subsidiaries other than the U.K. Note, the German Loan and the German
     Retained Loan,".

     Amendments to Section 2 of the Agreement

          Section 2(b)(i) of the Agreement is hereby amended in its entirety to
     read as follows:

          "(i) Subject to Section 2(c), Buyer agrees to pay to Seller, the Asset
     Sellers, the Share Sellers and the Note Sellers, at the Closing, in such
     amounts and to such accounts as Seller shall direct (subject to the
     Allocation Schedule attached to the Agreement), an amount equal to
     $810,000,000 in the aggregate (the "Preliminary Purchase Price"), by
     delivery of cash payable by wire transfer or delivery of other

                                        6

<PAGE>

     immediately available funds. The Preliminary Cash Purchase Price shall be
     subject to post-Closing adjustment as set forth below in Sections 2(f) and
     2(i)."

          Section 2(c) shall be amended by the addition of the following at the
     end of Section 2(c):

     "Notwithstanding any other provision of this Agreement to the contrary, in
the event that the Parties agree that the Closing shall occur prior to the
receipt of all necessary anti-trust approvals, authorizations or consents, or
the expiry of the applicable waiting period, in each case in Portugal, then (i)
at the Closing:

     (A) the Preliminary Purchase Price shall be reduced by $3,000,000,

     (B) the Acquired Assets shall exclude any Acquired Assets relating to the
Business in Portugal,

     (C) the Assumed Liabilities shall exclude any Assumed Liabilities relating
to the Business in Portugal,

     and (ii) within two business days following the receipt of all necessary
anti-trust approvals, authorizations or consents, or the expiry of the
applicable waiting period, in each case in Portugal:

     (A) Buyer shall pay to the applicable Asset Seller(s) (or an Affiliate of
Seller, as Seller shall direct) an amount equal to $3,000,000 by delivery of
cash payments by wire transfer or other immediately available funds, and

     (B) the relevant Asset Seller(s) shall transfer to Buyer (or an Affiliate
of Buyer, as Buyer shall direct) the Acquired Assets relating to the Business in
Portugal and Buyer (or an Affiliate of Buyer, as Buyer shall direct) shall
assume and become responsible for the Assumed Liabilities relating to the
Business in Portugal, in the cases of both (ii) (A) and (B) above, on

                                        7

<PAGE>

terms and conditions as set forth in this Agreement as if such transaction
occurred at the Closing."

          New Section 2(i) is hereby inserted into the Agreement immediately
     following Section 2(h) to read as follows:

     "(i) Reconciliation of German Cash.

          (i) At the time of the delivery of the Draft Closing Date Pro Forma
     Balance Sheet, Buyer shall notify Seller in writing if Buyer has determined
     that the amount of Cash held by Alpharma-Isis as of the Closing is less
     than or greater than E30,035,764.87. If Seller has any objections to the
     amount of Cash by Alpharma-Isis as of the Closing as determined by Buyer,
     Seller shall notify Buyer of such objections in the same manner as set
     forth with respect to objections regarding the Draft Closing Date Pro Forma
     Balance Sheet in Section 2(e) above, and all such objections regarding the
     amount of Cash in the German Business as of the Closing shall be resolved
     in the same manner as set forth with respect to objections regarding the
     Draft Closing Date Pro Forma Balance Sheet in Section 2(e) above.

          (ii) If the amount of Cash by Alpharma-Isis as of Closing as finally
     determined pursuant to Section 2(i)(i) above is less than
     E30,035,764.87, then Seller shall pay to Buyer an amount equal to the
     full amount of such deficiency by wire transfer or other delivery of
     immediately available funds within 3 business days after the date on which
     the Final Pro Forma Working Capital of the Business is finally determined
     pursuant to Section 2(e) above.

          (iii) If the amount of Cash by Alpharma-Isis as of Closing as finally
     determined pursuant to Section 2(i)(i) above is more than
     E30,035,764.87, then Buyer shall pay to Seller an amount equal to the
     full amount of such deficiency by wire transfer

                                        8

<PAGE>

     or other delivery of immediately available funds within 3 business days
     after the date on which the Final Pro Forma Working Capital of the Business
     is finally determined pursuant to Section 2(e) above."

     Amendment to Section 5(c) of the Agreement. Section 5(c) of the Agreement
is hereby amended by inserting the following sentence immediately following the
last sentence thereof:

          "Prior to the Closing, (i) Seller shall cause Alpharma-Isis not to
collect, extinguish or transfer the Bermuda Note and Seller shall cause Alpharma
Bermuda not to repay all or any portion of the Bermuda Note, (ii) Seller shall
cause Alpharma Bermuda not to collect, extinguish or transfer the German Loan
and Seller shall cause Alpharma-Isis not to repay all or any portion of the
German Loan and (iii) Seller shall cause Alpharma S.a.r.l. not to collect,
extinguish or transfer the U.K. Note and Seller shall cause Alpharma Holdings
Limited not to repay all or any portion of the U.K. Note."

     Amendments to Section 6 of the Agreement. New Sections 6(m) and 6(n) are
hereby inserted into the Agreement immediately following Section 6(l) to read as
follows:

     "(m) Repayment of Retained German Loan. Buyer shall cause Alpharma-Isis to
use its reasonable efforts to be legally permitted to repay the Retained German
Loan full as soon as reasonably practicable following the Closing and shall
cause Alpharma-Isis to repay in full the Retained German Loan as soon as such
repayment is legally permitted. If, on or prior to December 31, 2005,
Alpharma-Isis has not repaid in full the Retained German Loan, then, on or prior
to December 31, 2005, Alpharma-Isis shall deposit in an interest-bearing escrow
account established for this purpose an amount equal to the then outstanding
amount of the Retained German Loan (the "Escrow Amount"). The Escrow Amount
shall be applied in repaying the Retained German Loan as soon as Alpharma-Isis
is legally permitted to do so. All amounts of interest accrued with respect to
the Escrow Amount, if any, shall be held in the aforementioned

                                        9

<PAGE>

escrow account for the benefit of Alpharma Bermuda and shall be paid to Alpharma
Bermuda upon the repayment in full of the Retained German Loan. If, on or prior
to February 14, 2006, Alpharma-Isis has not repaid in full the Retained German
Loan, then, on February 14, 2006, Buyer shall repay, on behalf of Alpharma-Isis,
the then outstanding amount of the Retained German Loan and any and all amounts
held in such escrow account shall be immediately released to Alpharma-Isis.
Nothing in this Section 6(m) shall require Alpharma-Isis to make any repayment
(in part or in full) of the Retained German Loan if such repayment would result
in (i) a breach of the laws of any applicable jurisdiction, (ii) Alpharma-Isis
becoming insolvent or otherwise unable to satisfy its debts or other obligations
when due, or (iii) a breach by Alpharma-Isis of any agreement, arrangement or
understanding to which it is a party; provided that none of the foregoing
results shall relieve Buyer of the obligation to repay the then outstanding
amount of the Retained German Loan on behalf of Alpharma Isis on February 14,
2006.

     (n) Repayment of Cash. Buyer shall use its commercially reasonable efforts
to promptly pay to Seller (or an Affiliate of Seller, as Seller shall direct) an
amount equal to the aggregate amount of Cash held as of the Closing by the
Target Companies and their Subsidiaries (other than Alpharma (China) Holding
Limited, Alpharma (Foshan) Pharmaceutical Co., Ltd and Alpharma-Isis) that
Actavis is able either to freely use in the operation of the Business or legally
distribute to one or more of its Affiliates; provided, that, in any event Buyer
shall pay to Seller such amount no later than February 14, 2006."

     Amendment to Section 7(a)(xxvi) of the Agreement. Section 7(a)(xxvi) of the
Agreement is hereby amended in its entirety to read as follows: "(xxvi) the
Target Companies and their Subsidiaries shall not have any Indebtedness other
than the German Loan, the Retained German Loan and the U.K. Note;".

                                       10

<PAGE>

     Amendment to Section 9(e)(i) of the Agreement. The last sentence of Section
9(e)(i) of the Agreement is hereby amended in its entirety to read as follows:
"In furtherance of the cooperation provisions in Section 9(i), Seller will
furnish to Buyer as soon as reasonably practicable following the Closing (but in
any event, no later than 90 days after the Closing Date) such information and
assistance as Buyer may reasonably request to enable Buyer to determine the
desirability and consequences of making a Section 338(h)(10) Election with
respect to any of the U.S. Target Companies other than Alpharma USPD Inc., and
all determinations required pursuant to this clause (i) shall be made in good
faith."

     Amendment to Section 11(n) of the Agreement. Section 11(n) of the Agreement
is hereby amended in its entirety to read as follows:

     "(n) Allocation of Purchase Price. The Parties agree that the Purchase
Price (and other capitalized costs), together with the consideration represented
by Buyer's assumption of the Bermuda Note from Alpharma Bermuda (the "Allocated
Purchase Price"), will be allocated among the Asset Sellers, the Share Sellers
and the Note Sellers for all purposes (including Tax and financial accounting
purposes) as shown on (or pursuant to the methodology provided by) the
Allocation Schedule attached hereto. Within 90 days following the Closing Date
(or such later time as may be reasonable after the Purchase Price is
determined), Buyer shall prepare and deliver to Seller a schedule that further
allocates (i) the portion of the Allocated Purchase Price shown on the
Allocation Schedule for each Asset Seller, together with the Assumed Liabilities
applicable to such Asset Seller, among the Acquired Assets sold by such Asset
Seller to Buyer, and (ii) the portion of the Allocated Purchase Price shown on
the Allocation Schedule for each Share Seller among the Target Companies sold by
such Share Seller; provided that, if the Parties make a Section 338(h)(10)
election with respect to the sale of one or more U.S. Target Companies, such
schedule shall allocate the portion of the Allocated Purchase Price attributable
to each such Target Company, together with the liabilities of such Target
Company, among the assets of such Target Company. If Buyer does not receive
written notice of Seller's objection to such allocation within 30 days of its
delivery to Seller, then such allocation shall be the final

                                       11

<PAGE>

allocation and each of Seller, Buyer and their respective Affiliates shall
report, act, and file Tax Returns (including Internal Revenue Service Form 8594)
in all respects and for all purposes consistent with such allocation prepared by
Buyer. If the Purchase Price is subsequently adjusted, the adjusted Purchase
Price shall be reasonably allocated among the assets in a manner agreed by Buyer
and Seller consistent with the methodology previously used."

     Amendments to Amendment No. 2. The fifth, sixth and seventh paragraphs of
Amendment No. 2 shall be deleted in their entirety.

The eighth paragraph of Amendment No. 2 is hereby amended in its entirety to
read as follows:

          "At Closing, Actavis shall assume all liabilities and obligations of
Alpharma with respect to the Direct Purchaser Cases, including without
limitation the obligation to pay the Direct Purchaser Cases Settlement Amount;
provided that Alpharma shall (i) as soon as reasonably practicable, enter into
the settlement agreement, in the form most recently provided to Buyer (or its
advisers) prior to the date hereof, with respect to the Direct Purchaser Cases
with the class plaintiffs thereunder; (ii) pay an amount in cash equal to
US$6,700,000 either (A) into the escrow account contemplated by such settlement
agreement in accordance with the terms thereof or (B) if such escrow account has
not been established for such purpose as a result of any failure of the relevant
parties to enter into such agreement or the failure of the appropriate court
having jurisdiction over the Direct Purchaser Cases to approve such agreement or
otherwise, then, upon the written request of Actavis, into an account designated
in writing by Actavis; and (iii) upon Actavis' request, assign and transfer
Alpharma's rights, privileges and interest in such settlement agreement and the
escrowed funds to Actavis in a reasonably prompt manner."

                                       12

<PAGE>

     Amendment of Allocation Schedule. The Allocation Schedule attached to the
Agreement is hereby amended and restated and replaced with the "Allocation
Schedule (Revised)" attached hereto.

     Miscellaneous

     Incorporation by Reference. This Amendment incorporates by reference, and
is governed by, all of the terms of Section 11 of the Agreement as if such
Section was set forth in this Amendment.

     Ratification. Except as amended hereby, the Agreement, Amendment No. 1 and
Amendment No. 2 shall continue to be in full force and effect and are hereby in
all respects ratified and confirmed.

     Additional Amendments. To the extent that any of the representations or
warranties contained in Section 4 of the Agreement are not true and correct as a
result of any of the matters set forth herein, such representations and
warranties shall be deemed to be amended hereby such that none of the matters
set forth herein would make cause such representations or warranties not to be
true and correct.

     Consent and Waiver. To the extent that any of the matters set forth herein
are prohibited by Section 5(c) of the Agreement, Buyer hereby consents to Seller
and its Subsidiaries taking such actions as are required hereunder and hereby
waives any claims resulting therefrom.

                                    * * * * *

                                       13

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of
the date first above written.

                                        ALPHARMA INC.

                                        By:
                                            ------------------------------------
                                        Name: Ingrid Wiik
                                        Title: Vice Chairman of the Board,
                                               President and Chief Executive
                                               Officer

                                        ALPHARMA BERMUDA G.P.

                                        By: Alpharma (Bermuda) Inc.
                                        Its: General Partner

                                        By:
                                            ------------------------------------
                                        Name: Einar Thorstensen
                                        Title: President

                                        BARRE PARENT CORPORATION

                                        By:
                                            ------------------------------------
                                        Name: Matthew T. Farrell
                                        Title: President

                                        PUREPAC PHARMACEUTICAL HOLDINGS, INC.

                                        By:
                                            ------------------------------------
                                        Name: Robert F. Wrobel
                                        Title: Secretary

                                        ALPHARMA U.S. INC.

                                        By:
                                            ------------------------------------
                                        Name: Matthew T. Farrell
                                        Title: President

                                       14

<PAGE>

                                        ALPHARMA (U.K.) LIMITED

                                        By:
                                            ------------------------------------
                                        Name: Carl-Aake Carlsson
                                        Title: Director

                                        COX INVESTMENTS LIMITED

                                        By:
                                            ------------------------------------
                                        Name: Carl-Aake Carlsson
                                        Title: Director

                                        ALPHA-LUX INVESTMENTS S.A.R.L.

                                        By:
                                            ------------------------------------
                                        Name: Robert F. Wrobel
                                        Title: Manager

                                        By:
                                            ------------------------------------
                                        Name: Einar Thorstensen
                                        Title: Manager

                                        ALPHARMA APS

                                        By:
                                            ------------------------------------
                                        Name: Ingrid Wiik
                                        Title: Member of the Board

                                        By:
                                            ------------------------------------
                                        Name: Carl-Aake Carlsson
                                        Title: Member of Board

                                        ALPHARMA HOLDING, INC.

                                        By:
                                            ------------------------------------
                                        Name: Einar Thorstensen
                                        Title: Secretary

                                       15

<PAGE>

                                        ALPHARMA AS

                                        By:
                                            ------------------------------------
                                        Name: Ingrid Wiik
                                        Title: Chairman of the Board

                                        By:
                                            ------------------------------------
                                        Name: Carl-Aake Carlsson
                                        Title: Member of the Board

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]